首页 > 最新文献

Clinical Kidney Journal最新文献

英文 中文
Correction to: Mortality associated with the COVID-19 pandemic in the Swiss dialysis population beyond SARS-CoV-2 infection.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-02-14 eCollection Date: 2025-02-01 DOI: 10.1093/ckj/sfaf042

[This corrects the article DOI: 10.1093/ckj/sfae322.].

{"title":"Correction to: Mortality associated with the COVID-19 pandemic in the Swiss dialysis population beyond SARS-CoV-2 infection.","authors":"","doi":"10.1093/ckj/sfaf042","DOIUrl":"https://doi.org/10.1093/ckj/sfaf042","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/ckj/sfae322.].</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfaf042"},"PeriodicalIF":3.9,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breaking barriers: giving HOPE to people living with HIV and end-stage renal disease.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-28 eCollection Date: 2025-02-01 DOI: 10.1093/ckj/sfaf027
Matthias Diebold, Adnan Sharif
{"title":"Breaking barriers: giving HOPE to people living with HIV and end-stage renal disease.","authors":"Matthias Diebold, Adnan Sharif","doi":"10.1093/ckj/sfaf027","DOIUrl":"10.1093/ckj/sfaf027","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfaf027"},"PeriodicalIF":3.9,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological risk factors for acute kidney injury outcomes in hospitalized adult patients: a multicenter cohort study.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-23 eCollection Date: 2025-02-01 DOI: 10.1093/ckj/sfae426
Tomonori Takeuchi, A K M F Rahman, Lama Ghazi, Orson W Moe, Robert D Toto, Edward D Siew, Javier A Neyra, Orlando M Gutierrez

Background: Multiple studies have identified risk factors for acute kidney injury (AKI) in hospitalized patients, but less is known about factors associated with AKI severity, including non-recovery of AKI.

Methods: Retrospective cohort study of adults (≥18 years) hospitalized between 2014 and 2017 at three US academic medical centers. Study outcomes included incidence of AKI and non-recovery from AKI at hospital discharge in those who survived hospitalization. AKI was defined by KDIGO serum creatinine criteria. Non-AKI recovery was defined as persistent AKI stage ≥1 at time of discharge. Multivariable models assessed the association of risk factors for each outcome, focusing on race, diabetes, and obesity (BMI ≥ 30 versus <30 kg/m2), and adjusting for potential confounders.

Results: Among 56 056 patients included in the study (mean age 57, 25% Black, 48% women), 12 954 (23%) developed AKI. In adjusted models, Black race [odds ratio (OR) 1.26, 95% confidence interval (CI): 1.20, 1.32], diabetes (OR 1.14, 95% CI: 1.08, 1.19) and obesity (OR 1.14, 95% CI: 1.10, 1.20) were all associated with incident AKI. A total of 3591 of the 11 672 (30.8%) patients with AKI who survived until discharge had AKI non-recovery. In adjusted models, obesity (OR 1.27, 95% CI: 1.17, 1.39) was independently associated with higher risk of AKI non-recovery at hospital discharge.

Conclusions: Black race, diabetes, and obesity were associated with the development of AKI in hospitalized patients, but only obesity was associated with non-recovery from AKI at hospital discharge. These findings emphasize the growing relevance of obesity as an epidemiological risk factor of AKI.

{"title":"Epidemiological risk factors for acute kidney injury outcomes in hospitalized adult patients: a multicenter cohort study.","authors":"Tomonori Takeuchi, A K M F Rahman, Lama Ghazi, Orson W Moe, Robert D Toto, Edward D Siew, Javier A Neyra, Orlando M Gutierrez","doi":"10.1093/ckj/sfae426","DOIUrl":"10.1093/ckj/sfae426","url":null,"abstract":"<p><strong>Background: </strong>Multiple studies have identified risk factors for acute kidney injury (AKI) in hospitalized patients, but less is known about factors associated with AKI severity, including non-recovery of AKI.</p><p><strong>Methods: </strong>Retrospective cohort study of adults (≥18 years) hospitalized between 2014 and 2017 at three US academic medical centers. Study outcomes included incidence of AKI and non-recovery from AKI at hospital discharge in those who survived hospitalization. AKI was defined by KDIGO serum creatinine criteria. Non-AKI recovery was defined as persistent AKI stage ≥1 at time of discharge. Multivariable models assessed the association of risk factors for each outcome, focusing on race, diabetes, and obesity (BMI ≥ 30 versus <30 kg/m<sup>2</sup>), and adjusting for potential confounders.</p><p><strong>Results: </strong>Among 56 056 patients included in the study (mean age 57, 25% Black, 48% women), 12 954 (23%) developed AKI. In adjusted models, Black race [odds ratio (OR) 1.26, 95% confidence interval (CI): 1.20, 1.32], diabetes (OR 1.14, 95% CI: 1.08, 1.19) and obesity (OR 1.14, 95% CI: 1.10, 1.20) were all associated with incident AKI. A total of 3591 of the 11 672 (30.8%) patients with AKI who survived until discharge had AKI non-recovery. In adjusted models, obesity (OR 1.27, 95% CI: 1.17, 1.39) was independently associated with higher risk of AKI non-recovery at hospital discharge.</p><p><strong>Conclusions: </strong>Black race, diabetes, and obesity were associated with the development of AKI in hospitalized patients, but only obesity was associated with non-recovery from AKI at hospital discharge. These findings emphasize the growing relevance of obesity as an epidemiological risk factor of AKI.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfae426"},"PeriodicalIF":3.9,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney replacement therapies in the older person: challenges to decide the best option.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-22 eCollection Date: 2025-02-01 DOI: 10.1093/ckj/sfaf020
Jessica Selwood, Melanie Dani, Richard Corbett, Edwina A Brown

A multitude of challenges exist when supporting older adults in deciding on the optimal kidney replacement therapy (KRT), including frailty, comorbidity, cognitive impairment, dialysis modality, as well as local availability of services. The combination of these factors can determine treatment outcomes and quality of life (QoL), and as such the care of older people should be tailored to take these into account. Frailty in older people with chronic kidney disease (CKD) leads to higher rates of hospitalization, increased mortality, and a diminished QoL, while cognitive impairment, present in up to 50% of people with CKD, exacerbates these challenges and affects decision making. Dialysis, particularly haemodialysis, can accelerate physical and cognitive decline in frail older adults. Conversely, peritoneal dialysis (PD) presents a home-based alternative that may better support QoL, particularly for people wanting to prioritize treatment flexibility and independence. Assisted PD programmes have emerged as a valuable option for older people who cannot manage home-based care independently, improving access to KRT. Ultimately shared decision making should be employed when discussing KRT, incorporating patient goals, prognostic awareness, and QoL measures. There is also the emerging role of the geriatrician and the need for an integrated Comprehensive Geriatric Assessment. These elements support older adults to make informed choices that align with the individuals' values and health needs. In designing future health services to meet the needs of increasing numbers of older people, there needs to be increased access to assisted PD as well as multidisciplinary working to ensure patient-focused care surrounding KRT in older adults.

{"title":"Kidney replacement therapies in the older person: challenges to decide the best option.","authors":"Jessica Selwood, Melanie Dani, Richard Corbett, Edwina A Brown","doi":"10.1093/ckj/sfaf020","DOIUrl":"10.1093/ckj/sfaf020","url":null,"abstract":"<p><p>A multitude of challenges exist when supporting older adults in deciding on the optimal kidney replacement therapy (KRT), including frailty, comorbidity, cognitive impairment, dialysis modality, as well as local availability of services. The combination of these factors can determine treatment outcomes and quality of life (QoL), and as such the care of older people should be tailored to take these into account. Frailty in older people with chronic kidney disease (CKD) leads to higher rates of hospitalization, increased mortality, and a diminished QoL, while cognitive impairment, present in up to 50% of people with CKD, exacerbates these challenges and affects decision making. Dialysis, particularly haemodialysis, can accelerate physical and cognitive decline in frail older adults. Conversely, peritoneal dialysis (PD) presents a home-based alternative that may better support QoL, particularly for people wanting to prioritize treatment flexibility and independence. Assisted PD programmes have emerged as a valuable option for older people who cannot manage home-based care independently, improving access to KRT. Ultimately shared decision making should be employed when discussing KRT, incorporating patient goals, prognostic awareness, and QoL measures. There is also the emerging role of the geriatrician and the need for an integrated Comprehensive Geriatric Assessment. These elements support older adults to make informed choices that align with the individuals' values and health needs. In designing future health services to meet the needs of increasing numbers of older people, there needs to be increased access to assisted PD as well as multidisciplinary working to ensure patient-focused care surrounding KRT in older adults.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfaf020"},"PeriodicalIF":3.9,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ERA Registry Figure of the month Time trends in dialysis incidence across age groups and countries.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-20 eCollection Date: 2025-01-01 DOI: 10.1093/ckj/sfaf013
Vianda S Stel, Alberto Ortiz, Anneke Kramer
{"title":"ERA Registry Figure of the month Time trends in dialysis incidence across age groups and countries.","authors":"Vianda S Stel, Alberto Ortiz, Anneke Kramer","doi":"10.1093/ckj/sfaf013","DOIUrl":"https://doi.org/10.1093/ckj/sfaf013","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 1","pages":"sfaf013"},"PeriodicalIF":3.9,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11783564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinically meaningful eGFR slope as a surrogate endpoint differs across CKD stages and slope evaluation periods: the CKD-JAC study.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-13 eCollection Date: 2025-02-01 DOI: 10.1093/ckj/sfae398
Takahiro Imaizumi, Hirotaka Komaba, Takayuki Hamano, Masaomi Nangaku, Kenta Murotani, Takeshi Hasegawa, Naohiko Fujii, Kosaku Nitta, Yoshitaka Isaka, Takashi Wada, Shoichi Maruyama, Masafumi Fukagawa

Background: The slope of estimated glomerular filtration rate (eGFR) is a promising surrogate endpoint in patients with chronic kidney disease (CKD). However, current evidence is mainly derived from Western populations with CKD stages 1-3. In addition, stage-by-stage analysis has never been formally performed.

Methods: We analyzed data from the Chronic Kidney Disease Japan Cohort Study, which included a large proportion of patients with CKD stages 4 and 5. We estimated eGFR slopes over three evaluation periods (0.5, 1, and 2 years) using mixed effects models and examined their associations with kidney failure with replacement therapy across CKD stages.

Results: Of 2713 patients with an available 1-year eGFR slope, 985 subsequently initiated kidney replacement therapy. Overall, a slower eGFR decline was strongly associated with a lower risk of subsequent kidney failure with replacement therapy. The association was pronounced with higher baseline CKD stages and attenuated with shorter evaluation periods. The estimated deceleration in eGFR decline over 1 year associated with a 20% lower risk of subsequent kidney failure with replacement therapy was 1.91 (1.60-2.37), 1.12 (1.00-1.28), and 1.06 (0.81-1.60) ml/min/1.73 m2 per year in patients with CKD stages 3, 4, and 5, respectively.

Conclusion: Our results support the potential of eGFR slope as a surrogate across different stages of CKD in Asians and suggest that a shorter evaluation period than 2 years may be feasible for patients with late-stage CKD. Our findings provide valuable insights for the future design of clinical trials in CKD patients, especially those with more advanced CKD.

{"title":"Clinically meaningful eGFR slope as a surrogate endpoint differs across CKD stages and slope evaluation periods: the CKD-JAC study.","authors":"Takahiro Imaizumi, Hirotaka Komaba, Takayuki Hamano, Masaomi Nangaku, Kenta Murotani, Takeshi Hasegawa, Naohiko Fujii, Kosaku Nitta, Yoshitaka Isaka, Takashi Wada, Shoichi Maruyama, Masafumi Fukagawa","doi":"10.1093/ckj/sfae398","DOIUrl":"10.1093/ckj/sfae398","url":null,"abstract":"<p><strong>Background: </strong>The slope of estimated glomerular filtration rate (eGFR) is a promising surrogate endpoint in patients with chronic kidney disease (CKD). However, current evidence is mainly derived from Western populations with CKD stages 1-3. In addition, stage-by-stage analysis has never been formally performed.</p><p><strong>Methods: </strong>We analyzed data from the Chronic Kidney Disease Japan Cohort Study, which included a large proportion of patients with CKD stages 4 and 5. We estimated eGFR slopes over three evaluation periods (0.5, 1, and 2 years) using mixed effects models and examined their associations with kidney failure with replacement therapy across CKD stages.</p><p><strong>Results: </strong>Of 2713 patients with an available 1-year eGFR slope, 985 subsequently initiated kidney replacement therapy. Overall, a slower eGFR decline was strongly associated with a lower risk of subsequent kidney failure with replacement therapy. The association was pronounced with higher baseline CKD stages and attenuated with shorter evaluation periods. The estimated deceleration in eGFR decline over 1 year associated with a 20% lower risk of subsequent kidney failure with replacement therapy was 1.91 (1.60-2.37), 1.12 (1.00-1.28), and 1.06 (0.81-1.60) ml/min/1.73 m<sup>2</sup> per year in patients with CKD stages 3, 4, and 5, respectively.</p><p><strong>Conclusion: </strong>Our results support the potential of eGFR slope as a surrogate across different stages of CKD in Asians and suggest that a shorter evaluation period than 2 years may be feasible for patients with late-stage CKD. Our findings provide valuable insights for the future design of clinical trials in CKD patients, especially those with more advanced CKD.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfae398"},"PeriodicalIF":3.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11822292/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Equations for estimating resting energy expenditure in patients on peritoneal dialysis.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-13 eCollection Date: 2025-02-01 DOI: 10.1093/ckj/sfaf004
Xiao Xu, Nanzha Abi, Zhikai Yang, Tiantian Ma, Nan Zhang, Yingdong Zheng, Jie Dong

Background: In peritoneal dialysis (PD) patients, determining energy expenditure is essential for recommending energy intake in nutrition management.

Objective: We aimed to develop and validate a resting energy expenditure (REE) equation for patients with PD and compare it to previously available REE equations in dialysis patients.

Design: This cross-sectional study enrolled 200 patients with PD from two hospitals in Beijing, China. Stepwise linear regression analysis was used to derive a new REE equation (eREE-PD) based on actual REE (aREE) measured using indirect calorimetry (IC) in the development dataset. The eREE-PD value was then validated with aREE in the validation dataset and compared with values from existing equations obtained in general populations and those developed for chronic kidney disease and dialysis patients, in terms of bias, precision, and accuracy.

Results: The bias, precision, and accuracy of the eREE-PD equation were significantly better than those of the Harris-Benedict, WHO, and Schofield equations (P < .005) and comparable to the Mifflin equation (P = .541 for bias, .988 for precision, and .359 for accuracy), with IC as the reference method. Either bias, precision or accuracy of the eREE-PD were significantly better than eREE-V, eREE-Bscr, and eREE-CFFM equations significantly (P < .005) and similar to eREE-CKD, eREE-Bcrp, and eREE-Cweighht equations (P > .05 for bias, precision, and accuracy). The bias, precision, and accuracy of the eREE-PD equation were consistent across subgroups categorized by hs-CRP levels.

Conclusion: The eREE-PD equation, based on age, sex, and weight data, may serve as a reliable and practical tool for estimating REE in patients with PD, aiding in individualized nutritional management. However, external validation in other populations is required to confirm its generalizability beyond the studied cohort.

背景:在腹膜透析(PD)患者中,确定能量消耗对营养管理中建议能量摄入至关重要:在腹膜透析(PD)患者中,确定能量消耗对于在营养管理中推荐能量摄入至关重要:我们旨在开发并验证腹膜透析患者的静息能量消耗(REE)方程,并将其与之前可用的透析患者 REE 方程进行比较:这项横断面研究从中国北京的两家医院招募了 200 名透析患者。根据开发数据集中使用间接量热法(IC)测量的实际 REE(aREE),采用逐步线性回归分析法得出新的 REE 方程(eREE-PD)。然后用验证数据集中的 aREE 验证了 eREE-PD 值,并在偏差、精确度和准确性方面与从普通人群中获得的现有方程值以及为慢性肾病和透析患者开发的方程值进行了比较:以 IC 为参照方法,eREE-PD 方程的偏倚度、精确度和准确度明显优于 Harris-Benedict、WHO 和 Schofield 方程(偏倚度 P P = 0.541,精确度 P P = 0.988,准确度 P P = 0.359)。eREE-PD 的偏倚度、精确度或准确度均明显优于 eREE-V、eREE-Bscr 和 eREE-CFFM 方程(偏倚度、精确度和准确度均为 P crp,eREE-Cweighht 方程的偏倚度、精确度和准确度均为 P >.05)。在按 hs-CRP 水平分类的亚组中,eREE-PD 方程的偏差、精确度和准确性是一致的:eREE-PD方程基于年龄、性别和体重数据,可作为估算PD患者REE的可靠实用工具,有助于个体化营养管理。不过,还需要在其他人群中进行外部验证,以确认其在研究队列之外的通用性。
{"title":"Equations for estimating resting energy expenditure in patients on peritoneal dialysis.","authors":"Xiao Xu, Nanzha Abi, Zhikai Yang, Tiantian Ma, Nan Zhang, Yingdong Zheng, Jie Dong","doi":"10.1093/ckj/sfaf004","DOIUrl":"10.1093/ckj/sfaf004","url":null,"abstract":"<p><strong>Background: </strong>In peritoneal dialysis (PD) patients, determining energy expenditure is essential for recommending energy intake in nutrition management.</p><p><strong>Objective: </strong>We aimed to develop and validate a resting energy expenditure (REE) equation for patients with PD and compare it to previously available REE equations in dialysis patients.</p><p><strong>Design: </strong>This cross-sectional study enrolled 200 patients with PD from two hospitals in Beijing, China. Stepwise linear regression analysis was used to derive a new REE equation (eREE-PD) based on actual REE (aREE) measured using indirect calorimetry (IC) in the development dataset. The eREE-PD value was then validated with aREE in the validation dataset and compared with values from existing equations obtained in general populations and those developed for chronic kidney disease and dialysis patients, in terms of bias, precision, and accuracy.</p><p><strong>Results: </strong>The bias, precision, and accuracy of the eREE-PD equation were significantly better than those of the Harris-Benedict, WHO, and Schofield equations (<i>P</i> < .005) and comparable to the Mifflin equation (<i>P</i> = .541 for bias, .988 for precision, and .359 for accuracy), with IC as the reference method. Either bias, precision or accuracy of the eREE-PD were significantly better than eREE-V, eREE-B<sub>scr</sub>, and eREE-C<sub>FFM</sub> equations significantly (<i>P</i> < .005) and similar to eREE-CKD, eREE-B<sub>crp</sub>, and eREE-C<sub>weighht</sub> equations (<i>P</i> > .05 for bias, precision, and accuracy). The bias, precision, and accuracy of the eREE-PD equation were consistent across subgroups categorized by hs-CRP levels.</p><p><strong>Conclusion: </strong>The eREE-PD equation, based on age, sex, and weight data, may serve as a reliable and practical tool for estimating REE in patients with PD, aiding in individualized nutritional management. However, external validation in other populations is required to confirm its generalizability beyond the studied cohort.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfaf004"},"PeriodicalIF":3.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parathyroid gland volume and treatment resistance in patients with secondary hyperparathyroidism: a 4-year retrospective cohort study.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-10 eCollection Date: 2025-02-01 DOI: 10.1093/ckj/sfae391
Kazuhiko Kato, Akio Nakashima, Masamitsu Morishita, Ichiro Ohkido, Takashi Yokoo

Background: The role of parathyroid gland (PTG) ultrasonography in the management of secondary hyperparathyroidism after the introduction of calcimimetics remains unclear. Recent investigations have prompted renewed interest in the use of PTG ultrasonography for assessing treatment resistance to calcimimetics and determining the optimal timing for surgical intervention. This study aimed to explore the hypothesis that the PTG volume correlates with the calcimimetic dose.

Methods: We retrospectively observed outpatients undergoing haemodialysis at baseline and a 4-year follow-up. PTG volume was measured using ultrasonography between January and December 2017 and January and December 2021. We examined the association between baseline PTG volume and calcimimetic doses after 4 years.

Results: Of the 121 patients {median age 64 years [interquartile range (IQR) 54-72]}, 71 had PTG nodules on ultrasonography and the median total PTG volume was 34 mm3 (IQR 0-178). In the short dialysis vintage group, baseline parathyroid hormone levels tended to correlate with baseline calcimimetic doses; however, this trend was not observed in the extended dialysis vintage group. Baseline PTG volume correlated with the cinacalcet-equivalent calcimimetic dose (correlation coefficient 0.46; P < .001) after 4 years. The calcimimetic dose in the group with an estimated PTG volume >500 mm3 was ≈80 mg/day higher than that in the non-PTG nodule group after 4 years. In multivariate linear regression analysis, PTG volume >500 mm3 was associated with a high calcimimetic dose at 4 years in all analysis models.

Conclusions: Assessing PTG volume using ultrasonography may help predict high calcimimetic doses.

{"title":"Parathyroid gland volume and treatment resistance in patients with secondary hyperparathyroidism: a 4-year retrospective cohort study.","authors":"Kazuhiko Kato, Akio Nakashima, Masamitsu Morishita, Ichiro Ohkido, Takashi Yokoo","doi":"10.1093/ckj/sfae391","DOIUrl":"10.1093/ckj/sfae391","url":null,"abstract":"<p><strong>Background: </strong>The role of parathyroid gland (PTG) ultrasonography in the management of secondary hyperparathyroidism after the introduction of calcimimetics remains unclear. Recent investigations have prompted renewed interest in the use of PTG ultrasonography for assessing treatment resistance to calcimimetics and determining the optimal timing for surgical intervention. This study aimed to explore the hypothesis that the PTG volume correlates with the calcimimetic dose.</p><p><strong>Methods: </strong>We retrospectively observed outpatients undergoing haemodialysis at baseline and a 4-year follow-up. PTG volume was measured using ultrasonography between January and December 2017 and January and December 2021. We examined the association between baseline PTG volume and calcimimetic doses after 4 years.</p><p><strong>Results: </strong>Of the 121 patients {median age 64 years [interquartile range (IQR) 54-72]}, 71 had PTG nodules on ultrasonography and the median total PTG volume was 34 mm<sup>3</sup> (IQR 0-178). In the short dialysis vintage group, baseline parathyroid hormone levels tended to correlate with baseline calcimimetic doses; however, this trend was not observed in the extended dialysis vintage group. Baseline PTG volume correlated with the cinacalcet-equivalent calcimimetic dose (correlation coefficient 0.46; <i>P</i> < .001) after 4 years. The calcimimetic dose in the group with an estimated PTG volume >500 mm<sup>3</sup> was ≈80 mg/day higher than that in the non-PTG nodule group after 4 years. In multivariate linear regression analysis, PTG volume >500 mm<sup>3</sup> was associated with a high calcimimetic dose at 4 years in all analysis models.</p><p><strong>Conclusions: </strong>Assessing PTG volume using ultrasonography may help predict high calcimimetic doses.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfae391"},"PeriodicalIF":3.9,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11803308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CKD stage misclassification between estimated GFR and measured GFR in a clinical study of chronic kidney patients.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-09 eCollection Date: 2025-02-01 DOI: 10.1093/ckj/sfaf006
Richard B Dorshow, Martin P Debreczeny, Stuart L Goldstein
{"title":"CKD stage misclassification between estimated GFR and measured GFR in a clinical study of chronic kidney patients.","authors":"Richard B Dorshow, Martin P Debreczeny, Stuart L Goldstein","doi":"10.1093/ckj/sfaf006","DOIUrl":"10.1093/ckj/sfaf006","url":null,"abstract":"","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfaf006"},"PeriodicalIF":3.9,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The development and validation of a prediction model for post-AKI outcomes of pediatric inpatients.
IF 3.9 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-09 eCollection Date: 2025-02-01 DOI: 10.1093/ckj/sfaf007
Chao Zhang, Xiaohang Liu, Ruohua Yan, Xiaolu Nie, Yaguang Peng, Nan Zhou, Xiaoxia Peng

Background: Acute kidney injury (AKI) is common in hospitalized children. A post-AKI outcomes prediction model is important for the early detection of important clinical outcomes associated with AKI so that early management of pediatric AKI patients can be initiated.

Methods: Three retrospective cohorts were set up based on two pediatric hospitals in China, in which 8205 children suffered AKI during hospitalization. Two clinical outcomes were evaluated, i.e. hospital mortality and dialysis within 28 days after AKI occurrence. A Genetic Algorithm was used for feature selection, and a Random Forest model was built to predict clinical outcomes. Subsequently, a temporal validation set and an external validation set were used to evaluate the performance of the prediction model. Finally, the stratification ability of the prediction model for the risk of mortality was compared with a commonly used mortality risk score, the pediatric critical illness score (PCIS).

Results: The prediction model performed well for the prediction of hospital mortality with an area under the receiver operating curve (AUROC) of 0.854 [95% confidence interval (CI) 0.816-0.888], and the AUROC was >0.850 for both temporal and external validation. For the prediction of dialysis, the AUROC was 0.889 (95% CI 0.871-0.906). In addition, the AUROC of the prediction model for hospital mortality was superior to that of PCIS (< .0001 in both temporal and external validation).

Conclusions: The new proposed post-AKI outcomes prediction model shows potential applicability in clinical settings.

{"title":"The development and validation of a prediction model for post-AKI outcomes of pediatric inpatients.","authors":"Chao Zhang, Xiaohang Liu, Ruohua Yan, Xiaolu Nie, Yaguang Peng, Nan Zhou, Xiaoxia Peng","doi":"10.1093/ckj/sfaf007","DOIUrl":"10.1093/ckj/sfaf007","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) is common in hospitalized children. A post-AKI outcomes prediction model is important for the early detection of important clinical outcomes associated with AKI so that early management of pediatric AKI patients can be initiated.</p><p><strong>Methods: </strong>Three retrospective cohorts were set up based on two pediatric hospitals in China, in which 8205 children suffered AKI during hospitalization. Two clinical outcomes were evaluated, i.e. hospital mortality and dialysis within 28 days after AKI occurrence. A Genetic Algorithm was used for feature selection, and a Random Forest model was built to predict clinical outcomes. Subsequently, a temporal validation set and an external validation set were used to evaluate the performance of the prediction model. Finally, the stratification ability of the prediction model for the risk of mortality was compared with a commonly used mortality risk score, the pediatric critical illness score (PCIS).</p><p><strong>Results: </strong>The prediction model performed well for the prediction of hospital mortality with an area under the receiver operating curve (AUROC) of 0.854 [95% confidence interval (CI) 0.816-0.888], and the AUROC was >0.850 for both temporal and external validation. For the prediction of dialysis, the AUROC was 0.889 (95% CI 0.871-0.906). In addition, the AUROC of the prediction model for hospital mortality was superior to that of PCIS (<i>P </i>< .0001 in both temporal and external validation).</p><p><strong>Conclusions: </strong>The new proposed post-AKI outcomes prediction model shows potential applicability in clinical settings.</p>","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 2","pages":"sfaf007"},"PeriodicalIF":3.9,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Kidney Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1